secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001193125-23-243671
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics terminates ATM equity agreement, transfers Nasdaq listing to Capital Market
--------------------------------------------------------------------------------

- Terminated Equity Distribution Agreement with Oppenheimer; only $50,000 in net proceeds raised from 12,767 shares sold.
- Nasdaq approved transfer from Global Select Market to Capital Market effective Sept 28, 2023.
- Extended bid price compliance period to March 25, 2024; company plans reverse stock split if needed.
- Merger with Korro Bio remains pending; S-4 registration statement already filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523243671/0001193125-23-243671-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523243671/d506578d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-243671

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer